Author

S. W. Brady

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:clustering· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Assay:whole-genome sequencing· 2 Research Focus:cell type annotation· 1

Frequent Co-Authors

A. H. Bild· 2 shared J. A. McQuerry· 2 shared A. Farrell· 1 shared A. Frantz· 1 shared A. L. Cohen· 1 shared A. M. Gout· 1 shared A. Nath· 1 shared A. Patel· 1 shared

Activity by Year

2020-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. H. Bild

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Novel temporal and spatial patterns of metastatic colonization from rapid-autopsy tumor biopsies

X. Huang, Y. Qiao, S. W. Brady, R. E. Factor, E. Downs-Kelly, A. Farrell, J. A. McQuerry, G. Shrestha, D. F. Jenkins, W. E. Johnson, A. L. Cohen, A. H. Bild, G. T. Marth

This study uses rapid autopsy and whole genome sequencing to analyze metastatic evolution in a patient, identifying subclone incubators and four waves of metastatic expansion.

bioRxiv · Jun 3, 2021Cancer Biology

The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma.

M. Pan, C. Wright, R. Chapple, A. Zubair, M. Sandhu, J. Batchelder, J. Low, K. Blankenship, L. Wang, B. Gordon, P. Archer, S. W. Brady, S. Natarajan, M. Pozsgai, J. Schuetz, , P. Geeleher

This study identifies CX-5461 as a TOP2B inhibitor with selective activity in high-risk neuroblastoma but highlights safety concerns due to TOP2B off-target effects.

bioRxiv · Feb 25, 2021Cancer Biology

St. Jude Cloud a Pediatric Cancer Genomic Data Sharing Ecosystem

C. McLeod, A. M. Gout, X. Zhou, D. Rahbarinia, A. Thrasher, S. Newman, K. Birch, M. Macias, D. Finkelstein, J. Sunny, R. Mudunuri, B. A. Orr, M. Treadway, B. Davidson, T. Ard, , Z Wang

St. Jude Cloud provides a genomic data sharing ecosystem for pediatric cancer research, offering access to over 10,000 patient genomes and enabling analysis of cancer subtypes and mutational signatures.

bioRxiv · Aug 24, 2020Cancer Biology

A 'one-two punch' therapy strategy to target chemoresistance in estrogen receptor positive breast cancer

F. Chi, J. Liu, S. W. Brady, P. A. Cosgrove, A. Nath, J. A. McQuerry, S. Majumdar, P. J. Moos, J. T. Chang, M. Kahn, A. H. Bild

This study identifies a sequential therapy strategy using HDAC inhibitors to reverse chemotherapy-induced resistance in ER+ breast cancer by targeting cancer stem cell-like traits.

bioRxiv · Mar 12, 2020Cancer Biology